FDA Urges Centralized Clinical Trial Monitoring Over Frequent On-Site Visits - Guidance

Recent Duke University survey found that firms predominately conduct frequent visits to each clinical investigator site but "the rationale behind any specific monitoring approach does not appear to be evidence-based."